Ivosidenib has been approved for targeting relapsed/refractory IDH1-mutated MDS based on the results obtained from the AG120-C-001 MDS sub-study, which demonstrated complete response rates of approximately 40% and a median overall survival of 35.7 months [88,89]. The gene discussed is IDH1; the disease is myelodysplastic syndrome.